Literature DB >> 29385910

Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis.

Hafiz Shoaib Sarwar1, Muhammad Farhan Sohail1,2,3, Noushin Saljoughian4, Anees Ur Rehman1, Sohail Akhtar5, Akhtar Nadhman6, Masoom Yasinzai7, Howard E Gendelman8, Abhay R Satoskar4, Gul Shahnaz1,4.   

Abstract

The aim of this study was to evaluate mannose-anchored thiolated chitosan (MTC) based nanocarriers (NCs) for enhanced permeability, improved oral bioavailability and anti-parasitic potential of amphotericin B (AmB). Transgenic Leishmania donovani parasites expressing red fluorescent protein DsRed2 and imaging-flow cytometry was used to investigate parasitic burdens inside bone marrow-derived macrophages ex vivo. Cytokine estimation revealed that MTC nanocarriers activated the macrophages to impart an explicit immune response by higher production of TNF-α and IL-12 as compared to control. Cells treated with MTC NCs showed a significantly higher magnitude of nitrite and propidium iodide (PI) fluorescence intensity in contrast to cells treated with AmB. Concerning to apparent permeability coefficient (Papp) results, the MTC NCs formulation displayed more specific permeation across the Caco-2 cell monolayer as compared to AmB. The half-life of MTC NCs was about 3.3-fold persistent than oral AmB used as positive control. Also, t oral bioavailability of AmB was increased to 6.4-fold for MTC NCs compared to AmB for positive control. Acute oral evaluation indicated that MTC NCs were significantly less toxic compared to the AmB. Based on these findings, MTC NCs seems to be promising for significant oral absorption and improved oral bioavailability of AmB in leishmaniasis chemotherapy.

Entities:  

Keywords:  Oral bioavailability; acute toxicity; mannose receptors; permeation; thiolated chitosan nanocarriers

Mesh:

Substances:

Year:  2018        PMID: 29385910     DOI: 10.1080/21691401.2018.1430699

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  6 in total

1.  Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes.

Authors:  Guilherme S Ramos; Virgínia M R Vallejos; Gabriel S M Borges; Raquel M Almeida; Izabela M Alves; Marta M G Aguiar; Christian Fernandes; Pedro P G Guimarães; Ricardo T Fujiwara; Philippe M Loiseau; Lucas A M Ferreira; Frédéric Frézard
Journal:  Pharmaceutics       Date:  2022-05-05       Impact factor: 6.525

2.  Sensible graphene oxide differentiates macrophages and Leishmania: a bio-nano interplay in attenuating intracellular parasite.

Authors:  Aakriti Singh; Sandeep Sharma; Ganesh Yadagiri; Shabi Parvez; Ritika Gupta; Nitin Kumar Singhal; Nikhil Koratkar; Om Prakash Singh; Shyam Sundar; Vijayakumar Shanmugam; Shyam Lal Mudavath
Journal:  RSC Adv       Date:  2020-07-22       Impact factor: 4.036

3.  Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity.

Authors:  Diana Berenguer; Mª Magdalena Alcover; Marcella Sessa; Lyda Halbaut; Carme Guillén; Antoni Boix-Montañés; Roser Fisa; Ana Cristina Calpena-Campmany; Cristina Riera; Lilian Sosa
Journal:  Pharmaceutics       Date:  2020-02-12       Impact factor: 6.321

4.  Eplerenone nanocrystals engineered by controlled crystallization for enhanced oral bioavailability.

Authors:  Muhammad Ayub Khan; Muhammad Mohsin Ansari; Sadia Tabassam Arif; Abida Raza; Ho-Ik Choi; Chang-Wan Lim; Ha-Yeon Noh; Jin-Su Noh; Salman Akram; Hafiz Awais Nawaz; Muhammad Ammad; Abir Abdullah Alamro; Amani Ahmed Alghamdi; Jin-Ki Kim; Alam Zeb
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

5.  Effectiveness of Core-Shell Nanofibers Incorporating Amphotericin B by Solution Blow Spinning Against Leishmania and Candida Species.

Authors:  Ingrid Morgana Fernandes Gonçalves; Ítalo Martins Rocha; Emanuene Galdino Pires; Isis de Araújo Ferreira Muniz; Panmella Pereira Maciel; Jefferson Muniz de Lima; Iêda Maria Garcia Dos Santos; Roberta Bonan Dantas Batista; Eudes Leonnan Gomes de Medeiros; Eliton Souto de Medeiros; Juliano Elvis de Oliveira; Luiz Ricardo Goulart; Paulo Rogério Ferreti Bonan; Lúcio Roberto Cançado Castellano
Journal:  Front Bioeng Biotechnol       Date:  2020-10-30

Review 6.  Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis.

Authors:  Philippe M Loiseau; Sébastien Pomel; Simon L Croft
Journal:  Molecules       Date:  2020-09-09       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.